Volume 90, Issue 6 p. 518-521

Intra-ureteric capsaicin in loin pain haematuria syndrome: efficacy and complications

D. Playford

D. Playford

Departments of Urology,

Search for more papers by this author
H. Kulkarni

H. Kulkarni

Nephrology and

Search for more papers by this author
M. Thomas

M. Thomas

Nephrology and

Search for more papers by this author
J. Vivian

J. Vivian

Departments of Urology,

Search for more papers by this author
A. Low

A. Low

Departments of Urology,

Search for more papers by this author
J. Mander

J. Mander

Departments of Urology,

Search for more papers by this author
D. Perlman

D. Perlman

Anaesthesiology, Royal Perth Hospital, and

Search for more papers by this author
P. Finch

P. Finch

Perth Pain Management Centre, Perth, Western Australia

Search for more papers by this author
First published: 13 September 2002
Citations: 13

Abstract

Objective To evaluate the safety and efficacy of intra-ureteric capsaicin for loin pain haematuria syndrome (LPHS).

Patients and methods In an open prospective pilot study, four middle-aged patients (three women and one man) with LPHS resistant to therapies such as splanchnic nerve block, psychological treatment or renal autotransplantation (one) were assessed. An intra-ureteric infusion of capsaicin (30 mg/100 mL of 30% alcohol in saline) for 30 min with bladder irrigation was administered under general anaesthesia, with a subsequent intravenous patient-controlled narcotic analgesic pump for pain control. Double-concentration capsaicin was used for second infusions, if necessary when the response to the earlier infusion was inadequate or incomplete.

Results The first patient had experienced reduced pain levels for the first 3 months only, with no benefit from the subsequent treatments with higher doses of capsaicin (60 mg). The second patient with recurrent pain in an autotransplanted kidney had no benefit from either a 30 or 60 mg capsaicin infusion a month apart, but developed a fibrotic stricture at the transplant pelvi-ureteric junction, requiring pyelocystoplasty. The third patient with concurrent depression had no benefit from a 30-mg infusion of capsaicin. The fourth patient experienced no pain relief from a 30 mg infusion of capsaicin but developed proteinuria secondary to mesangial proliferative glomerulonephritis, ureteric inflammation needing stenting within 7 days of treatment and subsequently nephrectomy for a nonfunctioning kidney at 3 months.

Conclusion Intra-ureteric capsaicin was neither effective nor safe in LPHS; the contribution of the alcohol diluent cannot be excluded.